AU2017312499B2 - Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration - Google Patents

Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration Download PDF

Info

Publication number
AU2017312499B2
AU2017312499B2 AU2017312499A AU2017312499A AU2017312499B2 AU 2017312499 B2 AU2017312499 B2 AU 2017312499B2 AU 2017312499 A AU2017312499 A AU 2017312499A AU 2017312499 A AU2017312499 A AU 2017312499A AU 2017312499 B2 AU2017312499 B2 AU 2017312499B2
Authority
AU
Australia
Prior art keywords
tamoxifen
serm
subject
retinal
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017312499A
Other languages
English (en)
Other versions
AU2017312499A1 (en
Inventor
Wenxin MA
Xu Wang
Wai T. Wong
Lian ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2017312499A1 publication Critical patent/AU2017312499A1/en
Application granted granted Critical
Publication of AU2017312499B2 publication Critical patent/AU2017312499B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/398—Electrooculography [EOG], e.g. detecting nystagmus; Electroretinography [ERG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
AU2017312499A 2016-08-19 2017-08-10 Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration Active AU2017312499B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377439P 2016-08-19 2016-08-19
US62/377,439 2016-08-19
PCT/US2017/046359 WO2018034945A1 (en) 2016-08-19 2017-08-10 Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Publications (2)

Publication Number Publication Date
AU2017312499A1 AU2017312499A1 (en) 2019-01-31
AU2017312499B2 true AU2017312499B2 (en) 2023-02-02

Family

ID=59702849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017312499A Active AU2017312499B2 (en) 2016-08-19 2017-08-10 Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Country Status (5)

Country Link
US (1) US11040019B2 (enExample)
EP (1) EP3484463B1 (enExample)
JP (1) JP7100019B2 (enExample)
AU (1) AU2017312499B2 (enExample)
WO (1) WO2018034945A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7108715B2 (ja) * 2018-01-25 2022-07-28 パー ホール 乳房障害の治療をモニターするための組成物および方法
CN108295055B (zh) * 2018-02-26 2019-11-05 王晓琳 他莫昔芬在制备保护视网膜感光细胞的药物中的应用
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物
GB202000926D0 (en) * 2020-01-22 2020-03-04 Ucl Business Ltd Method of diagnosis
BR112022019113A2 (pt) * 2020-03-26 2022-12-06 Diamentis Inc Sistemas e métodos para processar dados de sinal da retina e identificar condições
WO2023150878A1 (en) 2022-02-09 2023-08-17 Diamentis Inc. Systems and methods for retinal stimulation and/or collecting retinal signal data

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040839A1 (ja) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4852579A (en) 1987-04-20 1989-08-01 Karl Storz Endoscopy Gmbh And Company Photocharacterization and treatment of normal abnormal and ectopic endometrium
JP2918991B2 (ja) 1990-05-25 1999-07-12 三菱瓦斯化学株式会社 漂白洗浄剤組成物
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
AU746007B2 (en) 1997-02-09 2002-04-11 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
DE19718826A1 (de) 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU2001271163A1 (en) 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
DE60106293T2 (de) 2000-10-25 2005-11-17 Eli Lilly And Co., Indianapolis Verfahren zur inhibierung von katarakten
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
US20050244461A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
CA2824517A1 (en) 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
US20130338145A1 (en) 2006-10-03 2013-12-19 Claire H. Mitchell Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
CN103211803A (zh) 2013-04-02 2013-07-24 苏州大学附属第一医院 他莫昔芬在治疗蛛网膜下腔出血后发生的早期脑损伤的应用
WO2014173374A1 (en) 2013-04-24 2014-10-30 Smart Brain s.r.o. Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
WO2016064959A1 (en) 2014-10-21 2016-04-28 Odin Biotech Two-layer ocular implant comprising a tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040839A1 (ja) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Koch, S. F. et al., "Halting progressive neurodegeneration in advanced retinitis pigmentosa", The Journal of Clinical Investigation, 2015, vol. 125, issue 9, pp. 3704-3713, DOI: 10.1172/JCI82462 *

Also Published As

Publication number Publication date
EP3484463A1 (en) 2019-05-22
US11040019B2 (en) 2021-06-22
JP2019532026A (ja) 2019-11-07
AU2017312499A1 (en) 2019-01-31
EP3484463B1 (en) 2020-02-12
JP7100019B2 (ja) 2022-07-12
US20190209497A1 (en) 2019-07-11
WO2018034945A1 (en) 2018-02-22
CA3032153A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
EP3484463B1 (en) Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
USRE50218E1 (en) Non-steroidal anti-inflammatory ophthalmic compositions
US8372814B2 (en) Ophthalmic formulations and uses thereof
US9289396B2 (en) Collagen-based implants for sustained delivery of drugs
US20110054031A1 (en) Ophthalmic NSAIDS as Adjuvants
US20070287749A1 (en) Bromfenac ophthalmic formulations and methods of use
EP3618841B1 (en) Ocular applications of matrix bound vesicles (mbvs)
US20160120912A1 (en) Compositions and method for promoting nerve growth and regeneration
WO2020191318A1 (en) Implantable ocular drug delivery devices and methods
TW201350124A (zh) 用於治療、控制、改善或逆轉乾眼症之病狀之醫藥組合物及方法
CA3032153C (en) Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
HK40015124B (en) Ocular applications of matrix bound vesicles (mbvs)
HK40015124A (en) Ocular applications of matrix bound vesicles (mbvs)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)